10.6084/m9.figshare.4499120.v1
Wang H.
Wang
H.
Pun P.H.
Pun
P.H.
Kwee L.
Kwee
L.
Craig D.
Craig
D.
Haynes C.
Haynes
C.
Chryst-Ladd M.
Chryst-Ladd
M.
Svetkey L.P.
Svetkey
L.P.
Patel U.D.
Patel
U.D.
Hauser E.R.
Hauser
E.R.
Pollak M.R.
Pollak
M.R.
Kraus W.E.
Kraus
W.E.
Shah S.H.
Shah
S.H.
Supplementary Material for: Apolipoprotein L1 Genetic Variants Are Associated with Chronic Kidney Disease but Not with Cardiovascular Disease in a Population Referred for Cardiac Catheterization
Karger Publishers
2016
Apolipoprotein L1
Chronic kidney disease
Cardiovascular disease
Gene polymorphism
Population genetics
2016-12-28 13:13:41
Journal contribution
https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_Apolipoprotein_L1_Genetic_Variants_Are_Associated_with_Chronic_Kidney_Disease_but_Not_with_Cardiovascular_Disease_in_a_Population_Referred_for_Cardiac_Catheterization/4499120
<p><b><i>Background:</i></b> While the association between <i>APOL1</i>
genetic variants and chronic kidney disease (CKD) has been established,
their association with cardiovascular disease (CVD) is unclear. This
study sought to understand CKD and cardiovascular risk conferred by <i>APOL1</i> variants in a secondary cardiovascular prevention population. <b><i>Methods:</i></b> Two risk variants in <i>APOL1</i> were genotyped in African-Americans (<i>n</i>
= 1,641) enrolled in the CATHGEN biorepository, comprised of patients
referred for cardiac catheterization at Duke University Hospital,
Durham, NC, USA (2001-2010). Individuals were categorized as noncarriers
(<i>n</i> = 722), heterozygote (<i>n</i> = 771), or homozygote carriers (<i>n</i> = 231) of <i>APOL1 </i>risk
alleles. Multivariable logistic regression and Cox proportional hazards
models adjusted for CVD risk factors were used to assess the
association between <i>APOL1</i> risk variants and prevalent and incident CKD, prevalent coronary artery disease (CAD), incident CVD events, and mortality. <b><i>Results:</i></b> The previously identified association between <i>APOL1 </i>variants and prevalent CKD was confirmed (OR: 1.85, 95% CI: 1.33-2.57, <i>p</i> = 0.0002). No statistically significant associations were detected between <i>APOL1</i>
variants and incident CKD or prevalent CAD, incident CVD events or
mortality. Age, type 2 diabetes, and ejection fraction at baseline were
significant clinical factors that predicted the risk of incident CKD in a
subgroup analysis of <i>APOL1</i> homozygous individuals. <b><i>Conclusion:</i></b><i>APOL1</i>
genetic variants are not associated with CAD or incident CVD events in a
cohort of individuals with a high burden of cardiometabolic risk
factors. In individuals with homozygous <i>APOL1</i> status, factors that predicted subsequent CKD included age, presence of type 2 diabetes, and ejection fraction at baseline.</p>